Skip to main content

RNAi Roundup

Premium

This summer, 151 scientists took the time to respond to our RNAi survey and give us a glimpse into the field. The vast majority of respondents say that they’re self-taught, having picked up the technique by reading journal papers. Far more of them are using siRNAs to induce RNAi, but a good number say they’ve at least tried hairpin DNAs. Below, you’ll find results from the survey indicating their experience with RNAi and vendors, as well as what they see as the main hurdles the technology must overcome.

File Attachments
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.